(Q39843788)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

review article

1 reference

title

Treatment of cutaneous T-cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

author name string

Vonderheid EC

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

Micaily B

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

publication date

1 October 1985

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

page(s)

673-687

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

PUVA treatment of erythrodermic and plaque type mycosis fungoides

7 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

The treatment of mycosis fungoides with a new agent, cyclophosphamide (Cytoxan)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Antilymphocyte globulin in the treatment of advanced Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Mycosis fungoides d'emblée: a rare presentation of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Cell volumes and dna distributions of normal and neoplastic human lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

DNA content analysis by flow cytometry and cytogenetic analysis in mycosis fungoides and Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Adjunct chemotherapy in the treatment of cutaneous malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Sézary syndrome: transformation to a high grade T-cell lymphoma after treatment with Cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of cutaneous lymphoma with etretinate

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of mycosis fungoides with heat-killed BCG and cord factor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Mechlorethamine desensitization in therapy for mycosis fungoides. Topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Palliative radiation treatment of cutaneous mycosis fungoides--a dose response

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Tilorone hydrochloride in the treatment of T cell lymphoproliferative cutaneous disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Lymphocyte transformation in patients with staged mycosis fungoides and sezary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Mycosis fungoides, nitrogen mustard and skin cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Anti-thymocyte globulin in treatment of T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Successful management of the Sézary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Nitrogen mustard (mechlorethamine) and UVB photocarcinogenesis: a dose response effect.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Prognostic signs and the management of the mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Failure of anti-thymocyte globulin treatment in T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

DNA content of mycosis fungoides cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Ultraviolet light treatment delays contact sensitization to nitrogen mustard

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Sezary's syndrome: a clinical evaluation of eight patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Dermatological aspects of the use of Cyclosporin A for prophylaxis of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

CHEMOTHERAPY WITH STREPTONIGRIN IN ADVANCED CANCER.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Effects of levamisole in Sézary syndrome. Apparent acceleration of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Differential loss of T lymphocyte markers in advanced cutaneous T cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Photochemotherapy for cutaneous T cell lymphoma. A follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

The rationale for curative radiotherapy in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Evaluation of fractionated total-body irradiation in patients with leukemia and disseminated lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Effect of high-dose thymidine infusions in patients with mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Clinical staging for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Combined chemotherapy (COP) in treatment of mycosis fungoides: report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Adriamycin therapy in advanced mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Megavolt Electron Irradiation for Localized Mycosis Fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Whole body surface electron irradiation in the treatment of mycosis fungoides. An evaluation of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Photochemotherapy for mycosis fungoides: a clinical and histological study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Cutaneous T-Cell Lymphomas: The Sézary Syndrome, Mycosis Fungoides, and Related Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of mycosis fungoides with cyclophosphamide and chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Retinoids in skin cancer and hyperproliferative skin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Azaribine for Mycosis Fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

HLA-DR-positive cells in large plaque (atrophic) parapsoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

OKT 9 reactivity in mycosis fungoides and large plaque (atrophic) parapsoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Total skin electron beam therapy in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Combined moderate dose electron beam radiotherapy and topical chemotherapy for cutaneous T-Cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Total skin electron beam and total nodal irradiation for treatment of patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Home ultraviolet phototherapy of early mycosis fungoides: preliminary observations

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Combination topical nitrogen mustard and photochemotherapy for mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Effectiveness of once weekly total skin electron beam therapy in mycosis fungoides and sezary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Oral methoxsalen photochemotherapy of psoriasis and mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of Resistant Malignant Lymphoma with Cyclophosphamide, Total Body Irradiation, and Transplantation of Cryopreserved Autologous Marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Leukapheresis in the treatment of Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

The treatment of mycosis fungoides.Adjuvant topical mechlorethamine after electron beam therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Ointment-based mechlorethamine treatment for mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of Sézary syndrome with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Alterations of lesions of mycosis fungoides lymphoma by direct imposition of delayed hypersensitivity reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of malignant lymphomas with methyl ester of streptonigrin (NSC 45384)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Structure and Expression of the Oncogene c-myc in Fresh Tumor Material from Patients with Hematopoietic Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

The treatment of mycosis fungoides with PUVA

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Therapy of mycosis fungoides with bleomycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Proliferation kinetics of the dermal infiltrate in cutaneous malignant lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Tumor-stage mycosis fungoides. A 32-year survival

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Total skin electron irradiation for mycosis fungoides: failure analysis and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Mechlorethamine hydrochloride solutions and ointment. Prolonged stability and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

The prognostic value of membrane markers and morphometric characteristics of lymphoid cells in blood and lymph nodes from patients with mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Cutaneous T-cell lymphoma, multilobated type

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of mycosis fungoides with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Bleomycin therapy in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Total Skin Electron Irradiation in Mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Failure of periodic ultraviolet radiation treatments to prevent sensitization to nitrogen mustard: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Topical mechlorethamine chemotherapy. Considerations on its use in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Prolonged remission of tumor-stage mycosis fungoides by topical immunotherpay

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Biophysical characterization of normal T-lymphocytes and Sézary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Prognostic significance of cytomorphology in the cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Acute myeloblastic leukemia following chemotherapy for mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Clinical implications of cytogenetic studies in cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Whole body electron therapy in mycosis fungoides—a successful translational technique achieved by modification of an established linear accelerator

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

The treatment of Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Cutaneous T-cell lymphoma: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Transfer factor in mycosis fungoides: three years experience

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2818%2930865-9

7 January 2021

10.1016/S0733-8635(18)30865-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3916174%20AND%20SRC:MED&resulttype=core&format=json

7 October 2019

1 reference